Abstract: The present invention provides a compound of Formula I: wherein R is H or R1 is H, halogen, C1-C3 alkyl, C3-C6 cycloalkyl, C1-C3 alkoxy, C2-C3 alkenyl, OCF3, R2 is H, halogen, C1-C3 alkyl, C1-C3 alkoxy, or C2-C4 alkenyl; R3 is NH2, or CH2NH2; and X is O, OCH2, OCH2CH2, OCH(CH3), CH2O, SCH2, CH2S, CH2, NHCH2, CH2NH, N(CH3)CH2, CH2CH2, C?C, or a bond, wherein X is connected to phenyl ring A at the ortho or the meta position, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I, or pharmaceutically acceptable salt thereof is useful for treating autoimmune and inflammatory diseases, such as atopic dermatitis and rheumatoid arthritis.

Abstract: The present invention relates to novel cGAS inhibitor compounds, to pharmaceutical compositions comprising the compounds, and to methods of using the compounds and compositions to treat certain pathological conditions.

Abstract: The present disclosure relates, in part, to a composition for promoting virolysis and/or inhibition of infection of a vims in a mammal, the composition comprising a lectin mutant. In certain embodiments, the lectin mutant comprises mutant cyanovirin N (CVN) and mutant Griffithsin (GRFT). The present disclosure further provides methods of treating, preventing, and/or ameliorating viral infection in a subject. In certain embodiments, the viral infection is caused by a vims selected from the group consisting of SARS-CoV-1, SARS-CoV-2, and HIV-I. The present disclosure further provides cyclic compounds useful for the treatment, prevention, and/or amelioration of HIV-I in a subject.

Abstract: The present invention provides a compound of Formula I: wherein R is H or R1 is H, halogen, C1-C3 alkyl, C3-C6 cycloalkyl, C1-C3 alkoxy, C2-C3 alkenyl, OCF3, R2 is H, halogen, C1-C3 alkyl, C1-C3 alkoxy, or C2-C4 alkenyl; R3 is NH2, or CH2NH2; and X is O, OCH2, OCH2CH2, OCH(CH3), CH2O, SCH2, CH2S, CH2, NHCH2, CH2NH, N(CH3)CH2, CH2CH2, C?C, or a bond, wherein X is connected to phenyl ring A at the ortho or the meta position, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I, or pharmaceutically acceptable salt thereof is useful for treating autoimmune and inflammatory diseases, such as atopic dermatitis and rheumatoid arthritis.

Abstract: The present invention provides a compound of Formula I: wherein R is H or R1 is H, halogen, C1-C3 alkyl, C3-C6 cycloalkyl, C1-C3 alkoxy, C2-C3 alkenyl, OCF3, R2 is H, halogen, C1-C3 alkyl, C1-C3 alkoxy, or C2-C4 alkenyl; R3 is NH2, or CH2NH2; and X is O, OCH2, OCH2CH2, OCH(CH3), CH2O, SCH2, CH2S, CH2, NHCH2, CH2NH, N(CH3)CH2, CH2CH2, C?C, or a bond, wherein X is connected to phenyl ring A at the ortho or the meta position, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I, or pharmaceutically acceptable salt thereof is useful for treating autoimmune and inflammatory diseases, such as atopic dermatitis and rheumatoid arthritis.

Abstract: The present invention includes novel cyclic peptides, and methods of using the same. The present invention further includes novel cyclic peptides conjugated with a gold nanoparticle, and methods of using the same.

Abstract: A pharmaceutical composition capable of forming free burst release effect in-situ forming implant useful for injection inside bone injuries without surgery is provided. This pharmaceutical composition includes; biodegradable polymer, selective estrogen receptor modulator, organic solvent and liquid lipid, solidifies upon contacting with the surrounding medium and form solid implant with compact framework by in-situ phase separation method to deliver the selective estrogen receptor modulator. This compact framework restores the porous structure of the implant by time which is essential in promoting bone healing.

Abstract: The present invention includes novel cyclic peptides of formula (I). The present invention further includes novel cyclic peptides conjugated with a gold nanoparticle, and methods of using the same. The invention further provides a pharmaceutical composition comprising at least one pharmaceutically acceptable carrier and at least one cyclic compound of the invention. The invention further provides a method of treating, reducing, or preventing HIV-1 infection in a mammal in need thereof, the method comprising administering to the mammal a therapeutically effective amount of at least one cyclic compound of the invention.

Abstract: The present invention includes novel cyclic peptides, and methods of using the same. The present invention further includes novel cyclic peptides conjugated with a gold nanoparticle, and methods of using the same.

Abstract: A mobile telecommunications network includes a core network (2020) having content processing means (2060, 2070) operable to provide a core network service relating to content, and a radio access network (700, 2003) having radio means for wireless communication with terminals (10) registered with the network, wherein the radio access network (700, 2003) includes a local source of content (1100). The telecommunications network is arranged to: deliver content from the local source of content (1100) to the terminal (10), to send to the core network (2020) an indication of the content delivered from the local source of content (1100) to the terminal (10), to obtain a copy of the content of the local source of content (1100) provided to the terminal (10), and to provide the content processing means (2060, 2070) core network service in relation to the copy of the content of the local source.

Abstract: The present invention includes novel cyclic peptides, and methods of using the same. The present invention further includes novel cyclic peptides conjugated with a gold nanoparticle, and methods of using the same.

Abstract: A mobile telecommunications network includes: a core network (2020) having content processing means (2055) operable to provide a core network service relating to content, and a radio access network (700, 2003) having radio means for wireless communication with a terminal (10) registered with the telecommunications network, wherein the radio access network (700, 2003) includes a local source of content (1100), wherein the telecommunications network is arranged to provide the content processing means (2055) core network service in relation to the content of the local source (1100), and wherein synchronization means is provided to synchronize the provision of core network service in relation to the content of the local source (1100) with communications with the terminal (10).

Abstract: The present invention includes novel cyclic peptides, and methods of using the same. The present invention further includes novel cyclic peptides conjugated with a gold nanoparticle, and methods of using the same.

Abstract: A mobile telecommunications network includes: a core network (2020) having content processing means (2055) operable to provide a core network service relating to content, and a radio access network (700, 2003) having radio means for wireless communication with a terminal (10) registered with the telecommunications network, wherein the radio access network (700, 2003) includes a local source of content (1100), wherein the telecommunications network is arranged to provide the content processing means (2055) core network service in relation to the content of the local source (1100), and wherein synchronisation means is provided to synchronise the provision of core network service in relation to the content of the local source (1100) with communications with the terminal (10).

Abstract: A mobile telecommunications network includes a core network (2020) having content processing means (2060, 2070) operable to provide a core network service relating to content, and a radio access network (700, 2003) having radio means for wireless communication with terminals (10) registered with the network, wherein the radio access network (700, 2003) includes a local source of content (1100). The telecommunications network is arranged to: deliver content from the local source of content (1100) to the terminal (10), to send to the core network (2020) an indication of the content delivered from the local source of content (1100) to the terminal (10), to obtain a copy of the content of the local source of content (1100) provided to the terminal (10), and to provide the content processing means (2060, 2070) core network service in relation to the copy of the content of the local source.

Abstract: The present invention includes compounds that are useful for treating or preventing a HIV-1 infection in a mammal. In certain embodiments, the compounds cause cell-free virolysis of an HIV-1 virus. The presented invention further includes a method of causing virolysis of a virus using the compounds described therein. The presented invention further includes a method of treating or preventing an HIV-1 infection in a mammal in need thereof using the compositions described therein.

Abstract: The present invention includes compounds that are useful for treating or preventing a HIV-1 infection in a mammal. In certain embodiments, the compounds cause cell-free virolysis of an HIV-1 virus. The presented invention further includes a method of causing virolysis of a virus using the compounds described therein. The presented invention further includes a method of treating or preventing an HIV-1 infection in a mammal in need thereof using the compositions described therein.

Abstract: Apparatus for monitoring breathing and for indicating a rate of breathing outside of a predetermined rate limit includes a sensing element adapted to be worn by a wearer so that the sensing element partakes of body motion due to breathing of the wearer and a detector, remote from the sensing element. The detector is responsive to motion of the sensing element for providing an alarm signal when the motion is outside of the predetermined rate limit. The sensing element contains no internal moving parts or circuitry, contains no battery or other source of electrical power whatsoever, requires no electrical contact with the wearer or with any other object, and requires no constraining or confining clothing, webbing, or the like.

Abstract: An optical shutter operated device includes a reflector to reflect incident light and a liquid crystal light shutter interposed in front of the reflector. A photovoltaic cell is disposed behind the shutter and is illuminated by the incident light thereby supplying a control voltage to the liquid crystal light shutter for causing it to alternate cyclically between a relatively transparent state and a relatively opaque state.